ライフサイエンスコーパス: brachytherapy

1 diotherapy; and 0.90 [95% CI, 0.85-0.95] for brachytherapy).

2 oning, and use for (131/137)Cs radiotherapy (brachytherapy).

3 Palladium-103 plaque brachytherapy.

4 y was transpupillary thermotherapy or plaque brachytherapy.

5 le surgery frequently is required for plaque brachytherapy.

6 cation with 54 cases treated with iodine-125 brachytherapy.

7 ients were treated with palladium-103 plaque brachytherapy.

8 external beam radiation therapy or invasive brachytherapy.

9 ated with either endoresection or iodine-125 brachytherapy.

10 es similar to those obtained with iodine-125 brachytherapy.

11 sing therapeutic alternative to conventional brachytherapy.

12 n essential component of quality outcomes in brachytherapy.

13 women in our sample, 4,671 (15.8%) received brachytherapy.

14 reatment with palladium-103 ((103)Pd) plaque brachytherapy.

15 based on differences in surgical staging or brachytherapy.

16 apy, primary androgen deprivation therapy or brachytherapy.

17 ectomy, external-beam radiation therapy, and brachytherapy.

18 melanomas are currently treated with plaque brachytherapy.

19 adiation, including external beam and plaque brachytherapy.

20 y treated by prostatectomy, radiotherapy, or brachytherapy.

21 nd nine (11%) patients underwent concomitant brachytherapy.

22 electron beam techniques and high-dose rate brachytherapy.

23 P classification testing after I(125) plaque brachytherapy.

24 , has been obtained with image-guided breast brachytherapy.

25 Gy, and high- or low-dose rate intracavitary brachytherapy.

26 ontrols treated with surgery plus iodine-125 brachytherapy.

27 d the complexity of performing intravascular brachytherapy.

28 x patients underwent angioplasty followed by brachytherapy.

29 ing multiple repeat interventions, including brachytherapy.

30 Iodine-125 plaque brachytherapy.

31 herapy are uncommon 5 years after episcleral brachytherapy.

32 ceived APBI using interstitial multicatheter brachytherapy.

33 to predict vision loss following episcleral brachytherapy.

34 for patients being evaluated for episcleral brachytherapy.

35 east irradiation or APBI using multicatheter brachytherapy.

36 SM and ACM during the first decade following brachytherapy.

37 ration biopsy of choroidal tumors undergoing brachytherapy.

38 d with uveal melanoma, 311 were treated with brachytherapy.

39 time of 16 months (range, 2-36 months) after brachytherapy.

40 apy, with the highest rate in high-dose-rate brachytherapy.

41 atherectomy (0.96 [0.53-1.7]), and vascular brachytherapy (0.60 [0.35-1.0]).

42 ty-adjusted life-years [QALYs]), followed by brachytherapy (10.57 QALYs), IMRT (10.51 QALYs), and rad

43 ), chemotherapy combined with teletherapy or brachytherapy (14%), enucleation (3%), or observation (2

44 radiotherapy (13.9 [95% CI, 6.7-21.2]), and brachytherapy (17.1 [95% CI, 7.8-26.6]).

45 m radiotherapy (11.7 [95% CI, 8.7-14.8]) and brachytherapy (20.5 [95% CI, 15.1-25.9]); and worsened b

46 with re-DES (58.1%), 132 underwent vascular brachytherapy (23.4%), and 104 were treated with convent

47 nts, -19.2% (-28.2 to -10.4) versus vascular brachytherapy, -23.4% (-36.2 to -10.8) versus bare metal

48 mastectomy was higher in women treated with brachytherapy (3.95%; 95% CI, 3.19%-4.88%) vs WBI (2.18%

49 vant pelvic radiotherapy (34.3% v 31.3%) and brachytherapy (33.6% v 31.0%; P < .05).

50 Of women treated with brachytherapy, 34.3% had a complication compared with 27

51 starting with external radiotherapy (63%) or brachytherapy (37%).

52 ectomy, 11.6% external-beam radiation, 13.3% brachytherapy, 4.0% cryoablation, and 14.4% androgen dep

53 Low-dose iodine-125 plaque brachytherapy (67.5-81 Gy at tumor apex) provides safe a

54 patients completed external radiation (99%), brachytherapy (75%), radiosensitizing therapy (98%), and

55 with teletherapy (31%), chemotherapy (18%), brachytherapy (9%), chemotherapy combined with telethera

56 external beam radiotherapy (21.8%), and 109 brachytherapy (9.6%).

57 When analyzed strictly as brachytherapy, (90)Y radioembolization planned by predic

58 characteristics, 35.2% of women treated with brachytherapy (95% CI, 28.6 to 41.9) had a complication

59 s the feasibility of tumor-specific prostate brachytherapy achievable with Yb-169 and actively target

60 Therefore, adjuvant APBI using multicatheter brachytherapy after breast-conserving surgery in patient

61 In recent years, use of breast brachytherapy after lumpectomy for early breast cancer h

62 One underwent FNAB only but did not undergo brachytherapy afterward.

63 High dose-rate (HDR) brachytherapy allows for control of the depth of radiati

64 brachytherapy followed by EBRT (n = 288) or brachytherapy alone (n = 280).

65 state-specific antigen, 10 to 20 ng/mL), LDR brachytherapy alone may be offered as monotherapy.

66 cancer (PC) -specific mortality (PCSM) after brachytherapy alone or in conjunction with androgen supp

67 stimate the risk of PCSM in men treated with brachytherapy alone or with supplemental AST, EBRT, or b

68 EBRT but not either supplement compared with brachytherapy alone was associated with a decreased risk

69 When compared with brachytherapy alone, a significant decrease in the risk

70 is review addresses the mechanisms that make brachytherapy an effective tool for restenosis and its a

71 sel failure was 21.6% (27/125) with vascular brachytherapy and 12.4% (32/259) with the sirolimus-elut

72 here have been sharp increases in the use of brachytherapy and androgen deprivation monotherapy, from

73 0.14 to 0.73; P = .006) in men treated with brachytherapy and both AST and EBRT as compared with nei

74 For the iodine-125 brachytherapy and endoresection groups, respectively, th

75 response parameters based on experience with brachytherapy and external-beam radiation therapy to pro

76 Rates of brachytherapy and hormonal therapy use, in particular, h

77 y, endoscopic ultrasound-guided interstitial brachytherapy and injection of therapeutic agents into t

78 h choroidal melanoma treated with iodine-125 brachytherapy and intraoperative FNAB from January 2005

79 tive benefit of alternative forms of RT (ie, brachytherapy and protons); target localization; the use

80 been reported in bare-metal stents (BMS) and brachytherapy and recently in drug-eluting stents.

81 Lesion length was similar between vascular brachytherapy and sirolimus-eluting stent patients (mean

82 s review focuses on the delivery devices for brachytherapy and their application in prostate, breast,

83 lanoma that cannot be handled with ruthenium-brachytherapy and therefore is a challenge for ophthalmo

84 n of radiation therapy techniques related to brachytherapy and three-dimensional conformal radiation

85 dal tumor, which was treated with iodine-125 brachytherapy and underwent intraoperative fine-needle a

86 d deep-tissue and bone complications between brachytherapy and WBI at 1 year of follow-up.

87 ted to be an abnormal finding after vascular brachytherapy and, possibly, implantation of drug-elutin

88 -up was 14.1% for re-DES, 17.5% for vascular brachytherapy, and 18.0% for conventional balloon angiop

89 All patients were treated with I-125 brachytherapy, and 2 received associated transpupillary

90 including stenting, laser photocoagulation, brachytherapy, and chemotherapy used singly or in combin

91 omen were treated with external irradiation, brachytherapy, and concurrent chemotherapy from January

92 l prostatectomy, external beam radiotherapy, brachytherapy, and cryotherapy will be reviewed.

93 s such as photodynamic therapy, intraluminal brachytherapy, and high-intensity ultrasound therapy may

94 ith various types of external beams and with brachytherapy, and it can be used systemically with targ

95 with external irradiation and intracavitary brachytherapy, and most received concurrent weekly cispl

96 therapy, sublobar resection, intraoperative brachytherapy, and radiofrequency ablation.

97 y, being used in external-beam radiotherapy, brachytherapy, and targeted radionuclide therapy.

98 l recurrence, including proton beam therapy, brachytherapy, and transpupillary thermotherapy used for

99 of sources, including x-rays, beam therapy, brachytherapy, and various injected radionuclides.

100 Local recurrences following brachytherapy are uncommon 5 years after episcleral brac

101 en patients died during follow-up: 11 in the brachytherapy arm vs 3 in the endoresection arm (20.4% a

102 erature seems to regard the effectiveness of brachytherapy as comparable to that of external beam rad

103 criteria after external-beam radiotherapy or brachytherapy as primary treatment.

104 As interventional radiotherapy (brachytherapy) as yet lacks any such long-term studies,

105 tended tumor retention allowed for effective brachytherapy, as indicated by extended survival time (>

106 therapy were imaged again after I-125 plaque brachytherapy at 6 and 18 months.

107 adenocarcinoma of the prostate treated with brachytherapy at the Prostate Cancer Foundation of Chica

108 He has decided against prostatectomy and brachytherapy because of strong personal preference.

109 with iodine 125 or ruthenium 106 episcleral brachytherapy between January 1, 2004, and December 30,

110 iving EBRT and androgen-deprivation therapy, brachytherapy boost (LDR or HDR) should be offered to el

111 ith or without androgen-deprivation therapy, brachytherapy boost (LDR or high-dose rate [HDR]) should

112 rapy (EBRT), radical prostatectomy (RP), and brachytherapy (BT) differed significantly in sociodemogr

113 l conformal radiation therapy [3-D CRT]), or brachytherapy (BT) were recontacted at a median of 6.2 y

114 However, brachytherapy can only be used in localized and relative

115 or retinoblastoma were developed; and plaque brachytherapy, chemoreduction, intra-arterial chemothera

116 median survival, was performed with previous brachytherapy clinical studies, which showed a proportio

117 Six deal with brachytherapy combined with external beam radiation ther

118 The main advantage of brachytherapy compared with external beam radiation (EBR

119 e significantly higher among women receiving brachytherapy compared with those receiving WBI.

120 der women with breast cancer, treatment with brachytherapy compared with WBI was associated worse wit

121 Particle teletherapy and brachytherapy continue to show promise in some clinical

122 egression response after iodine 125 (I(125)) brachytherapy correlates with class 2 GEP status.

123 No randomized trial evaluated brachytherapy, cryotherapy, robotic radical prostatectom

124 Newer high-dose-rate (HDR) brachytherapy delivery methods allow for the fractionati

125 Treatment with plaque brachytherapy demonstrates excellent outcomes in a commu

126 Brachytherapy devices have yielded promising results in

127 Brachytherapy did not reduce LR after SR.

128 f 8 acral CTCL lesions received low-dose HDR brachytherapy during a 3-year period.

129 However, prostatectomy, radiotherapy, and brachytherapy each can lead to distinct adverse effects.

130 omy with a single 24-gray dose of epimacular brachytherapy (EMB), delivered with an intraocular, hand

131 External beam and brachytherapy emissions are composed of photons, whereas

132 Brachytherapy enables the delivery of a high radiation d

133 tients treated with repeat episcleral plaque brachytherapy (EPBT) for locally recurrent posterior uve

134 Recently, electronic surface brachytherapy (ESB) has been described as a noninvasive

135 a higher prevalence of prior stent/vascular brachytherapy failure than did the rest of the populatio

136 The brachytherapy film used for treatment was the RIC Confor

137 idal melanoma, intraoperative FNAB, and post-brachytherapy follow-up of 1 to 6 years (mean, 2.7 +/- 1

138 e randomly assigned to either vaginal radium brachytherapy followed by EBRT (n = 288) or brachytherap

139 study investigated the role of low-dose HDR brachytherapy for acral CTCL lesions.

140 eluting stent implantation to intravascular brachytherapy for in-stent stenosis of bare metal stents

141 The role of intravascular brachytherapy for in-stent stenosis of drug eluting sten

142 To evaluate low- vs high-dose plaque brachytherapy for juxtapapillary choroidal melanoma.

143 GFR) ((177)Lu-T-AuNP) as a novel neoadjuvant brachytherapy for LABC.

144 update the Cancer Care Ontario guideline on brachytherapy for patients with prostate cancer to accou

145 A total of 375 eyes treated with episcleral brachytherapy for posterior uveal melanoma from January

146 ter prostatectomy, external radiotherapy, or brachytherapy for prostate cancer.

147 ter prostatectomy, external radiotherapy, or brachytherapy for prostate cancer.

148 To date, the literature on renal artery brachytherapy for restenosis consists of several singula

149 etermine the safety and efficacy of vascular brachytherapy for the treatment of diffuse in-stent rest

150 angiographic outcomes compared with vascular brachytherapy for the treatment of restenosis within a b

151 Vision loss following episcleral brachytherapy for uveal melanoma is difficult to predict

152 6 to 2011; all patients who underwent plaque brachytherapy for uveal melanoma were included.

153 y-based institutional experience with plaque brachytherapy for uveal melanomas with a focus on local

154 olving partial breast irradiation, including brachytherapy, for breast cancer; and currently accruing

155 melanoma who were treated with I(125) plaque brachytherapy from January 2007 through January 2011 wit

156 e review of patients who underwent MammoSite brachytherapy from October 2003 to March 2007.

157 -PMB was carried out transperineally using a brachytherapy grid under TRUS guidance.

158 segment was 29.5% (31/105) for the vascular brachytherapy group and 19.8% (45/227) for the sirolimus

159 s required in 19.2% (24/125) of the vascular brachytherapy group and 8.5% (22/259) of the sirolimus-e

160 success was 99.2% (124/125) in the vascular brachytherapy group and 97.3% (250/257) in the sirolimus

161 Patients in the brachytherapy group reported having long-lasting urinary

162 as observed in 11 patients in the iodine-125 brachytherapy group vs only 1 patient in the endoresecti

163 Compared with the vascular brachytherapy group, minimal lumen diameter was larger i

164 nal information is available at www.asco.org/Brachytherapy-guideline and www.asco.org/guidelineswiki

165 Prostate brachytherapy has become a common treatment modality for

166 Vascular brachytherapy has demonstrated its efficacy in limiting

167 Brachytherapy has disseminated into clinical practice as

168 These findings show that this nanoseed-based brachytherapy has the potential to provide a theranostic

169 These injectable brachytherapy hydrogels were used to treat two aggressiv

170 ranial ependymomas treated with interstitial brachytherapy (IBT).

171 artery chemotherapy in 5 (16%) eyes, plaque brachytherapy in 5 (16%), transpupillary thermotherapy (

172 e potential advantages for the role of focal brachytherapy in early PCa.

173 external beam radiation therapy (EBRT) with brachytherapy in men with prostate cancer.

174 as a relatively infrequent event after I-125 brachytherapy in our series.

175 e of PTEN, indicating clinical potential for brachytherapy in patients with intermediate and high ris

176 , and the management of recurrence following brachytherapy in patients with posterior uveal melanoma,

177 acteristics of treatment failure after I-125 brachytherapy in patients with uveal melanoma treated an

178 e of an intraoperative high-dose rate of 32P brachytherapy in selected cases of recalcitrant diffuse

179 troversy regarding the role of intravascular brachytherapy in the setting of growing use of drug elut

180 One patient was treated with brachytherapy in two SVGs but had a recurrence four mont

181 hip exists following treatment with prostate brachytherapy; in other words, dosimetry matters and poo

182 ris melanoma regression after (103)Pd plaque brachytherapy included decreased intrinsic tumor vascula

183 The modern technique of prostate brachytherapy includes three components, (1) treatment p

184 erformed: men were treated at diagnosis with brachytherapy, intensity-modulated radiation therapy (IM

185 Treatment (brachytherapy, intensity-modulated radiation therapy, or

186 y include high-intensity focused ultrasound, brachytherapy, interstitial laser thermotherapy, stereot

187 y available methods of APBI are interstitial brachytherapy, intracavitary brachytherapy, intraoperati

188 re interstitial brachytherapy, intracavitary brachytherapy, intraoperative radiotherapy, and three-di

189 Brachytherapy is a common clinical technique involving i

190 Brachytherapy is a method for delivering partial-breast

191 Brachytherapy is a radiation treatment that uses an impl

192 ancer and < 50% myometrial invasion, vaginal brachytherapy is as effective as pelvic radiation therap

193 The utility of intravascular brachytherapy is being rethought in relation to its use

194 Brachytherapy is commonly used among Medicare beneficiar

195 in-stent stenosis, the role of intravascular brachytherapy is decreasing primarily due to the simplic

196 Brachytherapy is described as the short distance treatme

197 needle aspiration biopsy immediately before brachytherapy is excellent for obtaining tumor aspirate

198 ries and case reports demonstrate that renal brachytherapy is feasible and safe.

199 Intracoronary brachytherapy is the only adjuvant therapy that has been

200 Although vascular brachytherapy is the only approved therapy for restenosi

201 Intratumoral radiation therapy - 'brachytherapy' - is a highly effective treatment for sol

202 apy, especially interventional radiotherapy (brachytherapy), is a technically feasible treatment tech

203 re or choose active treatment, low-dose rate brachytherapy (LDR) alone, EBRT alone, and/or radical pr

204 Adjuvant brachytherapy may reduce LR This multicenter randomized

205 Epimacular brachytherapy may reduce the need for frequent anti-VEGF

206 as combining interstitial and intracavitary brachytherapy, may be more appropriate for improving the

207 After brachytherapy, mean tumor thickness decreased to 0.9+/-0

208 Traditional low-dose-rate brachytherapy methods require extended periods of patien

209 Vascular brachytherapy (n = 125) or the sirolimus-eluting stent (

210 = 4), followed by cryotherapy (n = 3) and/or brachytherapy (n = 3).

211 For the pancreatic tumors, ELP brachytherapy (n=6) induced significant growth inhibitio

212 ies under investigation include interstitial brachytherapy, new chemotherapeutic agents that cross th

213 e isotope options for patients receiving LDR brachytherapy; no recommendation can be made for or agai

214 mising for their application for neoadjuvant brachytherapy of LABC.

215 xudative retinal detachment resolution after brachytherapy of posterior uveal melanoma.

216 Vascular brachytherapy of true aorto-ostial lesions (n = 34) was

217 A total of 107 patients underwent plaque brachytherapy, of which 88 had follow-up data available.

218 The efficacy of vascular brachytherapy on angiographic and clinical outcomes is e

219 gest differences in efficacy for one form of brachytherapy or another.

220 radical prostatectomy, and in 5-9% following brachytherapy or cryotherapy after prostate cancer.

221 ity-of-life domains among patients receiving brachytherapy or radiotherapy.

222 procedure rates declined with later year of brachytherapy (OR, 0.93/yr; P < .01).

223 privation (OR, 1.31; P < .01), later year of brachytherapy (OR, 1.03/yr; P = .02), higher Charlson co

224 l prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance.

225 nd radiotherapy (external-beam radiotherapy, brachytherapy, or both) are the most widely accepted cur

226 ters before and after radical prostatectomy, brachytherapy, or external-beam radiotherapy.

227 ore appropriate for improving the quality of brachytherapy plans associated with inadequate target co

228 e whether IPSA could improve cervical cancer brachytherapy plans giving D90 < 6 Gy (with 7 Gy per fra

229 annealing (IPSA) can improve the quality of brachytherapy plans, and we wanted to examine whether IP

230 dollars); of brachytherapy plus IMRT versus brachytherapy plus 3D-CRT was $10,789; of MIRP versus op

231 sus 3D-CRT was $10,986 (in 2008 dollars); of brachytherapy plus IMRT versus brachytherapy plus 3D-CRT

232 ng of $282 million for IMRT, $59 million for brachytherapy plus IMRT, and $4 million for MIRP, compar

233 roups; however, patients undergoing vascular brachytherapy presented with more complex lesions and a

234 Epimacular brachytherapy produces stable visual acuity in most part

235 The precise and targeted nature of brachytherapy provides a number of key benefits for the

236 s case series demonstrates that low-dose HDR brachytherapy provides excellent palliation for local co

237 nt incorporation procedure, palladium-103, a brachytherapy radioisotope in clinical practice, was coa

238 iotherapy, intensity-modulated radiotherapy, brachytherapy, radiosurgery, and photodynamic therapy fo

239 The most common long-term brachytherapy-related complication was radiation maculop

240 The most common long-term brachytherapy-related complications were radiation macul

241 n men who opted for radical prostatectomy or brachytherapy, reported close attention to current PSA,

242 een treated by external-beam radiotherapy or brachytherapy, respectively.

243 Perioperative brachytherapy results in a better local control rate tha

244 Brachytherapy results in the most irritative urinary sym

245 l treatment failure in this series, and post-brachytherapy retinal detachment occurred in 3 eyes.

246 A few reports have suggested stereotactic brachytherapy (SBT) with implantation of iodine-125 ((12

247 ation is designed to perform fully automated brachytherapy seed placement within a closed MR imager.

248 raphy is mainly used for biopsy guidance and brachytherapy seed placement.

249 study, accurate placement and MR imaging of brachytherapy seeds in the prostate were demonstrated.

250 Electronic surface brachytherapy should be used with caution, particularly

251 nter randomized trial compares SR to SR with brachytherapy (SRB).

252 .7% v 81.7%; P < .001) and for men receiving brachytherapy, supplemental IMRT increased significantly

253 iew highlights the rationale and outcomes of brachytherapy techniques.

254 ation approval and Medicare reimbursement of brachytherapy technology.

255 y feasible with both newer external-beam and brachytherapy technology.

256 ne and the other comprised mice treated with brachytherapy that received 1.11 MBq of (1)(7)(7)Lu-DOTA

257 Furthermore, with HDR brachytherapy, the radiation dose distribution can be ta

258 adjunct to needle biopsy immediately before brachytherapy to minimize these complications and preser

259 Although the application of HDR brachytherapy to soft tissue sarcoma is relatively new,

260 uveal melanoma after primary treatment with brachytherapy, transpupillary thermotherapy, proton beam

261 Brachytherapy treatment was well tolerated, with clinica

262 Recurrent tumors were managed by repeat brachytherapy, TTT, or enucleation.

263 Frequency of brachytherapy use as an alternative to external-beam rad

264 Brachytherapy use was also more likely in women with non

265 Brachytherapy use was more likely in women with lymph no

266 Logistic regression modeled predictors of brachytherapy use.

267 previously undescribed form of experimental brachytherapy using plaques loaded with I-125 seeds.

268 The percent of patients receiving brachytherapy varied substantially across HRRs, ranging

269 ent recurrence rates are high, with vascular brachytherapy (VBT) affording the best results.

270 oduction of two major advances, the vascular brachytherapy (VBT) and the drug-eluting stents (DES).

271 Late total occlusion after vascular brachytherapy (VBT) continues to be a serious complicati

272 We analyzed the effects of vascular brachytherapy (VBT) on ostial in-stent restenosis (ISR).

273 T (PORTEC-1; n = 714) or EBRT versus vaginal brachytherapy (VBT; PORTEC-2; n = 427).

274 laims codes identified patients treated with brachytherapy versus external-beam radiation after BCS f

275 r lumpectomy 6952 patients were treated with brachytherapy vs 85,783 with WBI.

276 CI, 85.94%-89.18%) in patients treated with brachytherapy vs 87.04% (95% CI, 86.69%-87.39%) in patie

277 ostatectomy, external beam radiotherapy, and brachytherapy vs active surveillance.

278 Recurrence-free survival 24 months after brachytherapy was 75% (95% CI, 19-89.1).

279 Brachytherapy was associated with a 16.9% higher rate of

280 Brachytherapy was associated with more frequent infectio

281 Morbidity after prostate brachytherapy was common, though invasive procedures wer

282 cleral FNAB at the time of iodine-125 plaque brachytherapy was not associated with endophthalmitis, o

283 Gamma brachytherapy was performed in 19% (10/54) of patients.

284 ongoing questions regarding efficacy, breast brachytherapy was rapidly incorporated into the care of

285 Brachytherapy was the most effective and least expensive

286 rom 1995 to 2016 and treated with episcleral brachytherapy were included.

287 ients had a 20% restenosis rate 1 year after brachytherapy, when Doppler ultrasound was used for foll

288 LDR mimicking brachytherapy, which is used successfully in the clinic,

289 Adult UM patients treated with I(125) plaque brachytherapy who had concurrent tumor biopsy at the tim

290 gests that the need to perform intravascular brachytherapy will be in fewer than one in 20 patients.

291 and suggests that the need for intravascular brachytherapy will significantly decrease.

292 Vascular brachytherapy with 192Ir is safe and reduces the rate of

293 There were 5,621 men who had brachytherapy with at least 2 years of follow-up.

294 eatment included external beam radiation and brachytherapy with concurrent cisplatin chemotherapy.

295 Vascular brachytherapy with either gamma or beta sources results

296 Palladium 103 plaque brachytherapy with or without extraocular muscle surgery

297 eceived surgery (26%), external RT (38%), or brachytherapy with or without RT (36%).

298 r the feasibility of tumor-specific prostate brachytherapy with Yb-169 and gGNRs.

299 Study for tumors of the same size treated by brachytherapy without biopsy.

300 Analyses were adjusted for age at brachytherapy, year of treatment, and known PC prognosti